Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Free Cash Flow of -$22.2 million for Q1 2026, down 89.0% year-over-year from -$202.0 million in Q1 2025, and down 28.86% quarter-over-quarter from -$17.2 million in Q4 2025.
Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Free Cash Flow for 17 consecutive years, with -$22.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 89.0% year-over-year to -$22.2 million; the TTM figure through Mar 2026 stood at -$107.9 million (down 101.9% YoY), while the FY2025 annual figure was -$97.4 million, down 59.19% from the prior year.
- Free Cash Flow retreated to -$22.2 million in Q1 2026 per WHWK's latest filing, from -$17.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.0 million in Q3 2022 and bottomed at -$53.6 million in Q2 2025.
- Historically, Free Cash Flow has averaged -$17.1 million across 5 years, with a median of -$14.8 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow soared 54.0% — and 2025, when it plunged 407.07%.
- Whitehawk Therapeutics' Free Cash Flow stood at -$11.7 million in 2022, then advanced by 18.56% to -$9.5 million in 2023, then slumped by 79.27% to -$17.1 million in 2024, then fell by 0.94% to -$17.2 million in 2025, then dropped by 28.86% to -$22.2 million in 2026.
- Business Quant data shows WHWK's Free Cash Flow at -$22.2 million in Q1 2026, -$17.2 million in Q4 2025, and -$14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | -14.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.37 Mn |
| Jun 30, 2026 | -14.37 Mn |
| Mar 31, 2026 | -22.21 Mn |
| Mar 31, 2026 | -22.21 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -14.83 Mn |
| Sep 30, 2025 | -14.83 Mn |
| Jun 30, 2025 | -53.62 Mn |
| Jun 30, 2025 | -53.62 Mn |
| Mar 31, 2025 | -11.75 Mn |
| Mar 31, 2025 | -11.75 Mn |
| Dec 31, 2024 | -17.07 Mn |
| Dec 31, 2024 | -17.07 Mn |
| Sep 30, 2024 | -14.04 Mn |
| Sep 30, 2024 | -14.04 Mn |
| Jun 30, 2024 | -10.58 Mn |
| Jun 30, 2024 | -10.58 Mn |
| Mar 31, 2024 | -19.52 Mn |
| Mar 31, 2024 | -19.52 Mn |